SomaLogic, Inc.

CM Life Sciences II Inc. (Nasdaq: CMII), a life sciences-focused special purpose acquisition company sponsored by CM Life Sciences II LLC, completed its initial public offering in 2020. On March 29, 2021, the company filed an 8-K with the Securities and Exchange Commission disclosing a definitive business combination agreement with SomaLogic, Inc., a proteomics company headquartered in Boulder, Colorado, whose SomaScan platform is used for large-scale protein biomarker discovery and translational research. At the time of the filing, CMII had moved into the announced business combination stage, targeting the healthcare and diagnostics sector. Sign up for full filing data, deal timelines, and SPAC-level analytics on CMII and thousands of other transactions at SpacDesk.